IRVINE, Calif., Jan. 18, 2023 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the highly anticipated national launch of JUVÉDERM ® VOLUX™ XC. The long ...

JUVÉDERM® VOLUX™ XC IS THE FIRST AND ONLY HYALURONIC ACID (HA) FILLER TO RECEIVE U.S. FDA APPROVAL FOR IMPROVING JAWLINE DEFINITION IRVINE, Calif., Aug. 3, 2022 /PRNewswire/ -- Today, Allergan ...

Allergan Data on File, JUVÉDERM ® Ultra XC Patient Label, 2023. Allergan Data on File, BOTOX ® Cosmetic Prescribing Information, 2023. Allergan Data on File, JUVÉDERM ® Awards, 2014-2022, 2022.

Juvéderm Ultra XC has a higher concentration of hyaluronic acid than Restylane and Volbella (the next filler up). "The G prime is lower than both Restylane and Volbella, giving the lips a softer ...

IRVINE, Calif., Aug. 1, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the first ever JUVÉDERM® Day on Wednesday, August 16, 2023. The celebration recognizes ...

Juvéderm Volux XC is an injectable gel filler containing hyaluronic acid (HA). The approval is supported by data from a pivotal phase 3 study (ClinicalTrials.gov Identifier: NCT03712137 ...

IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc., (NYSE:AGN) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVÉDERM VOLUMA™ XC ...

IRVINE, Calif., June 15, 2020 /PRNewswire/ -- Today Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the FDA approval of JUVÉDERM® V ...

Revenue from these products is still growing at healthy rates -- Juvederm's sales rose almost 5% year over year in the company's Q4 -- and contributing heavily to overall revenue.

Juvéderm Voluma XC provided immediate improvement in moderate to severe temple hollowing that lasted for more than 1 year (responder rate for the treatment group at 13-month follow-up: 73.3%).